A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia (NCT06767683)
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
Who can join: Review the eligibility criteria below.
Location: Alkermes Investigational Site — Cullman, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (49 Sites)
Showing the first 25 of 49 sites.
- Alkermes Investigational Site — Cullman, Alabama
- Alkermes Investigator Site — Phoenix, Arizona
- Alkermes Investigational Site — Little Rock, Arkansas
- Alkermes Investigational Site — Los Angeles, California
- Alkermes Investigator Site — San Francisco, California
- Alkermes Investigational Site — Stanford, California
- Alkermes Investigational Site — Boulder, Colorado
- Alkermes Investigational Site — Colorado Springs, Colorado
- Alkermes Investigational Site — Brandon, Florida
- Alkermes Investigational Site — Miami, Florida
- Alkermes Investigational Site — Winter Park, Florida
- Alkermes Investigational Site — Atlanta, Georgia
- Alkermes Investigational Site — Macon, Georgia
- Alkermes Investigational Site — Stockbridge, Georgia
- Alkermes Investigational Site — Peoria, Illinois
- Alkermes Investigational Site — Kansas City, Kansas
- Alkermes Investigational Site — Lansing, Michigan
- Alkermes Investigational Site — Sterling Heights, Michigan
- Alkermes Investigational Site — Lincoln, Nebraska
- Alkermes Investigational Site — Middletown, New Jersey
- Alkermes Investigational Site — Denver, North Carolina
- Alkermes Investigational Site — Huntersville, North Carolina
- Alkermes Investigational Site — Canton, Ohio
- Alkermes Investigational Site — Cincinnati, Ohio
- Alkermes Investigational Site — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (888) 235-8008
Email: clinicaltrials@alkermes.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Narcolepsy Type 1
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — Cullman, Alabama
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Miami, Florida
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — Colorado Springs, Colorado
Explore by condition: All Narcolepsy Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.